Mouillot P, Witko-Sarsat V, Wislez M
Service de pneumologie et de soins intensif, Hôpital François Mitterrand, Université de Bourgogne Franche-Comté, Dijon, France; Inserm U1016, Institut Cochin, Université de Paris, Île de France, Paris, France.
Unité de formation et de recherche Médecine Paris Centre - Université de Paris, Île de France, Paris, France; Inserm U1016, Institut Cochin, Université de Paris, Île de France, Paris, France.
Rev Mal Respir. 2022 Sep;39(7):587-594. doi: 10.1016/j.rmr.2022.06.007. Epub 2022 Jul 20.
Lung cancer remains the leading cause of cancer mortality in France. Research has shown that immune cells play a major role in tumor growth, angiogenesis and promotion of metastasis. While the density of intra-tumoral adaptive immune cell infiltrate is associated with a favorable prognosis, the presence of polynuclear neutrophils (innate immune cells) is associated in different types of cancer with a poor prognosis. The reviewed studies underline the abundance of intra-tumoral neutrophils involved in tumor progression by their immunosuppressive activity. More specifically, it has been shown that the neutrophil/lymphocyte (N/L) ratio is a prognostic marker. Different mechanisms promoting tumor progression have been identified, particularly the pro-angiogenic and immunosuppressive activities of neutrophils. However, under certain conditions, they can also exert effective anti-tumor activity through their interactions with the adaptive immune system. The complexity of the role of neutrophils in oncology resides in the diversity of subpopulations and their plasticity under the influence of the tumor environment. In this review, we will discuss the different properties of neutrophils not only as pro- and anti-tumor effector cells, but also as immunomodulatory cells, and we will conclude by considering therapeutic perspectives in lung cancer.
肺癌仍然是法国癌症死亡的主要原因。研究表明，免疫细胞在肿瘤生长、血管生成和转移促进中起主要作用。虽然肿瘤内适应性免疫细胞浸润的密度与良好预后相关，但多核中性粒细胞（固有免疫细胞）的存在在不同类型癌症中与不良预后相关。所综述的研究强调了肿瘤内中性粒细胞因其免疫抑制活性而参与肿瘤进展的情况。更具体地说，已经表明中性粒细胞/淋巴细胞（N/L）比率是一种预后标志物。已经确定了促进肿瘤进展的不同机制，特别是中性粒细胞的促血管生成和免疫抑制活性。然而，在某些条件下，它们也可以通过与适应性免疫系统的相互作用发挥有效的抗肿瘤活性。中性粒细胞在肿瘤学中的作用的复杂性在于亚群的多样性及其在肿瘤环境影响下的可塑性。在本综述中，我们将不仅讨论中性粒细胞作为促肿瘤和抗肿瘤效应细胞，而且作为免疫调节细胞的不同特性，并将通过考虑肺癌的治疗前景来得出结论。
